


| business CMAB Biopharma's development and manufacturing platform successfully completes Q-1802 bispecific antibody project for QureBio within 9 months PR Newswire Asia |
|
China and the US; Completion of the project demonstrates the significant speed to clinic achievable with CMAB's fully integrated development and manufacturing platform; QureBio's bispecific antibody Q-1802 will enter clinical trials to assess treatment of solid tumors such as gastric cancer.
Posted: 2020-05-13 14:53:00
|
If you are a broadcaster or Christian program producer you can schedule a 15 min FREE consultation with an EGR specialist to help you evaluate all possible Int'l broadcasting options.
We will call you back at a number and time of your convenience, and will gladly answer any question that you may have on how to broadcast your Christian message worldwide.